Roles of β-Lactamases and Porins in Activities of Carbapenems and Cephalosporins against Klebsiella pneumoniae
Open Access
- 1 July 1999
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 43 (7) , 1669-1673
- https://doi.org/10.1128/aac.43.7.1669
Abstract
Two clinical isolates of extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae were noted to be less susceptible than expected to imipenem. Both were missing outer membrane proteins that serve as channels for antibiotic entry. The role of β-lactamase in resistance was investigated by eliminating the original ESBL and introducing plasmids encoding various ESBLs and AmpC β-lactamase types, by studying the effect of an increased inoculum, and by evaluating interactions with β-lactamase inhibitors. The contribution of porin deficiency was investigated by restoring a functional ompK36 gene on a plasmid. Plasmids encoding AmpC-type β-lactamases provided resistance to imipenem (up to 64 μg/ml) and meropenem (up to 16 μg/ml) in strains deficient in porins. Carbapenem resistance showed little inoculum effect, was not affected by clavulanate but was blocked by BRL 42715, and was diminished if OmpK36 porin was restored. Plasmids encoding TEM- and SHV-type ESBLs conferred resistance to cefepime and cefpirome, as well as to earlier oxyimino-β-lactams. This resistance was magnified with an increased inoculum, was blocked by clavulanate, and was also lowered by OmpK36 porin restoration. In addition, SHV-2 β-lactamase had a small effect on carbapenem resistance (imipenem MIC, 4 μg/ml, increasing to 16 μg/ml with a higher inoculum) when porins were absent. In K. pneumoniae porin loss can thus augment resistance provided either by TEM- or SHV-type ESBLs or by plasmid-mediated AmpC enzymes to include the latest oxyimino-β-lactams and carbapenems.Keywords
This publication has 42 references indexed in Scilit:
- Efficacy of Cefepime in the Treatment of Infections Due to Multiply Resistant Enterobacter SpeciesClinical Infectious Diseases, 1996
- Relative importances of outer membrane permeability and group 1 beta-lactamase as determinants of meropenem and imipenem activities against Enterobacter cloacaeAntimicrobial Agents and Chemotherapy, 1995
- Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistanceAntimicrobial Agents and Chemotherapy, 1994
- Sequences of MGH-1, YOU-1, and YOU-2 extended-spectrum beta-lactamase genesAntimicrobial Agents and Chemotherapy, 1993
- Activity of meropenem against imipenem-resistant bacteria and selection in vitro of carbapenem-resistantEnterobacteriaceaeEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992
- Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in Enterobacter aerogenesJournal of Antimicrobial Chemotherapy, 1991
- Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porinsAntimicrobial Agents and Chemotherapy, 1991
- Enhanced resistance to cefotaxime and imipenem associated with outer membrane protein alterations in Enterobacter aerogenesJournal of Antimicrobial Chemotherapy, 1990
- The Use of Analytical Isoelectric Focusing for Detection and Identification of -LactamasesJournal of General Microbiology, 1975
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970